Early rhythm control for AF beneficial for older patients with high comorbidity burden

In patients with recently diagnosed atrial fibrillation and a high comorbidity burden, early rhythm control therapy markedly reduced CV death, stroke or hospitalization for HF or ACS, according to new data from the EAST-AFNET 4 trial.
However, early rhythm control was not effective in patients with fewer CV comorbidities compared with usual care, and therapy-related bradycardia and drug toxicity also increased.
“Rhythm control therapy is often recommended for patients with symptoms to improve quality of life, and it is also recommended to patients who are younger and healthier,”

In patients with recently diagnosed atrial fibrillation and a high comorbidity burden, early rhythm control therapy markedly reduced CV death, stroke or hospitalization for HF or ACS, according to new data from the EAST-AFNET 4 trial.
However, early rhythm control was not effective in patients with fewer CV comorbidities compared with usual care, and therapy-related bradycardia and drug toxicity also increased.
“Rhythm control therapy is often recommended for patients with symptoms to improve quality of life, and it is also recommended to patients who are younger and healthier,”